Renal function and long-term mortality in patients with asymptomatic carotid atherosclerosis

Summary

Renal dysfunction is a risk factor for mortality in patients with atherosclerosis. Estimated glomerular filtration rate (eGFR), cystatin C (CysC) and beta-2-microglobulin (B2M) are measures of renal function. It remains unclear, which of these parameters is the strongest predictor of outcome in patients with atherosclerosis. All-cause and cardiovascular mortality were prospectively investigated in 1,065 consecutive patients with asymptomatic carotid atherosclerosis. During a median follow-up of 6.3 years 275 patients died (25.8%), including 182 (66.2%) from cardiovascular causes. Estimated GFR, CysC and B2M were all significantly and independently associated with mortality. Inclusion of the renal parameters CysC and B2M but not of eGFR into a model with established cardiovascular risk factors improved the C-statistics significantly (p=0.0035 and 0.036, respectively; p=0.182 for eGFR). The net reclassification improvement (NRI) was 32.4% (p<0.0001) for CysC, 29% (p<0.0001) for B2M, and 16.5% (p=0.019) for eGFR. The integrated discrimination improvement (IDI) was 0.014 (p=0.0009) for CysC and 0.011 (p=0.005) for B2M while it was not significant for eGFR. Results were consistent for various subgroups with different extent of atherosclerosis. In summary, CysC and B2M were found to be independent predictors for mortality and had superior predictive value compared to eGFR in patients with asymptomatic carotid atherosclerosis. The clinical importance of these findings has to be validated in larger studies with a community-based approach.

Keywords

Atherosclerosis - risk factors - cerebrovascular disease - clinical studies

• References

• 1 Amin AP, Spertus JA, Reid KJ. et al. The prognostic importance of worsening renal function during an acute myocardial infarction on long-term mortality. Am Heart J 2010; 160: 1065-1071.
• 2 Lee M, Saver JL, Huang WH. et al. Impact of elevated cystatin C level on cardiovascular disease risk in predominantly high cardiovascular risk populations: a meta-analysis. Circ Cardiovasc Qual Outcomes 2010; 03: 675-683.
• 3 Go AS, Chertow GM, Fan D. et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
• 4 Kurth T, de Jong PE, Cook NR. et al. Kidney function and risk of cardiovascular disease and mortality in women: a prospective cohort study. Br Med J 2009; 338: b2392.
• 5 Hoke M, Amighi J, Mlekusch W. et al. Cystatin C and the risk for cardiovascular events in patients with asymptomatic carotid atherosclerosis. Stroke 2010; 41: 674-679.
• 6 Muntner P, Hamm LL, Kusek JW. et al. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 2004; 140: 9-17.
• 7 Shlipak MG, Fried LF, Crump C. et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003; 107: 87-92.
• 8 Fujimaki T, Kato K, Yoshida T. et al. Association of genetic variants with myocardial infarction in Japanese individuals with chronic kidney disease. Thromb Haemost 2009; 101: 963-968.
• 9 Dhingra R, Sullivan LM, Fox CS. et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007; 167: 879-885.
• 10 Lau WL, Festing MH, Giachelli CM. Phosphate and vascular calcification: Emerging role of the sodium-dependent phosphate co-transporter PiT-1. Thromb Haemost 2010; 104: 464-470.
• 11 Schillinger M, Exner M, Mlekusch W. et al. Serum albumin predicts cardiac adverse events in patients with advanced atherosclerosis – interrelation with traditional cardiovascular risk factors. Thromb Haemost 2004; 91: 610-618.
• 12 Levey AS, Coresh J, Greene T. et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-254.
• 13 Rule AD, Larson TS, Bergstralh EJ. et al. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med 2004; 141: 929-937.
• 14 Soares AA, Eyff TF, Campani RB. et al. Glomerular filtration rate measurement and prediction equations. Clin Chem Lab Med 2009; 47: 1023-1032.
• 15 Ix JH, Shlipak MG, Chertow GM. et al. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 2007; 115: 173-179.
• 16 Dieterle F, Perentes E, Cordier A. et al. Urinary clusterin, cystatin C, beta2-micro-globulin and total protein as markers to detect drug-induced kidney injury. Nat Biotechnol 2010; 28: 463-469.
• 17 Schillinger M, Exner M, Mlekusch W. et al. Inflammation and carotid artery risk for atherosclerosis study (ICARAS). Circulation 2005; 111: 2203-2209.
• 18 International Statistical Classification of Diseases and Related Health problems 10th revision. http://apps.who.int/classifications/apps/icd/icd10online Accessed August 27, 2011.
• 19 Levey AS, Stevens LA, Schmid CH. et al A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
• 20 DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-845.
• 21 Pencina MJ, D'Agostino Sr RB, D'Agostino Jr RB. et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-172.
• 22 Zethelius B, Berglund L, Sundström J. et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008; 358: 2107-2116.
• 23 Hillis GS, Croal BL, Buchan KG. et al. Renal function and outcome from coronary artery bypass grafting: impact on mortality after a 2.3-year follow-up. Circulation 2006; 113: 1056-1062.
• 24 Stevens LA, Li S, Kurella Tamura M. et al. Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2011; 57: S9-16.
• 25 Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40: 221-226.
• 26 Shinkai S, Chaves PH, Fujiwara Y. et al. Beta2-microglobulin for risk stratification of total mortality in the elderly population: comparison with cystatin C and C-reactive protein. Arch Intern Med 2008; 168: 200-206.
• 27 Manzano-Fernández S, Januzzi Jr JL, Boronat-Garcia M. et al. β-trace protein and cystatin C as predictors of long-term outcomes in patients with acute heart failure. J Am Coll Cardiol 2011; 57: 849-858.
• 28 Manetti L, Pardini E, Genovesi M. et al. Thyroid function differently affects serum cystatin C and creatinine concentrations. J Endocrinol Invest 2005; 28: 346-349.